Prognostic Factors, Treatment and Outcome in a Turkish Population with Endometrial Stromal Sarcoma

  • Donertas, Ayla (Department Obstetrics and Gynaecology, Tepecik Training and Research Hospital) ;
  • Nayki, Umit (Department Obstetrics and Gynaecology, Erzincan University, Medical Faculty) ;
  • Nayki, Cenk (Department Obstetrics and Gynaecology, Erzincan University, Medical Faculty) ;
  • Ulug, Pasa (Department Obstetrics and Gynaecology, Erzincan University, Medical Faculty) ;
  • Gultekin, Emre (Department Obstetrics and Gynaecology, Tepecik Training and Research Hospital) ;
  • Yildirim, Yusuf (Department Obstetrics and Gynaecology, Tepecik Training and Research Hospital)
  • Published : 2015.03.04


Purpose: To analyze treatment modalities and prognostic factors in patients with Stage I-II endometrial stromal sarcoma (ESS). Materials and Methods: Twenty four patients (nineteen with low-grade ESS [LGESS] and five with high-grade ESS [HGESS]) were assessed retrospectively in terms of general characteristics, prognostic factors, treatment methods and survival. Results: Twenty patients were at Stage I and three were at Stage II. The stage of one patient could not be determined. With respect to age and comorbidity, no statistically significant difference was found among disease-free survival (DFS) (p=0.990; p=0.995). However, DFS was significantly shorter in Stage II than Stage I patients (p=0.002). It was also significantly shorter in HGESS patients than in LGESS patients (p=0.000). There was no statistically significant differences among the overall survival (OVS) times of patients with respect to age at diagnosis and comorbid disease (p=0.905; p=0.979) but OVS was significantly shorter in patients with HGESS (p=0.00) and Stage II disease (p=0.001). No statistically significant difference was found with respect to OVS between patients who received radiotherapy (RT) and those who did not receive RT (p=0.055). It was not statistically possible to include other treatment modalities in the analysis because of the small sample size. Conclusions: Grade and stage of a tumour were found to be the most important prognostic factors. It was not possible to determine the optimal surgical method and the effect of adjuvant treatment since the number of cases was insufficient.


Endometrial stromal sarcoma;prognostic factors;treatment methods


  1. Amant F, De Knijf A, Van Calster B, et al (2007). Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer, 97, 1194-9.
  2. Barney B, Tward JD, Skidmore T, Gaffney DK (2009). Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer, 19, 1232-8.
  3. Berchuck A, Rubin SC, Hoskins WJ, et al (1990). Treatment of endometrial stromal tumors. Gynecol Oncol, 36, 60-5.
  4. Bodner K, Adler BB, Obermair A, et al (2001). Prognostic parameters in endometrial stromal sarcoma: A clinicopathologic study in 31 patients. Gynecol Oncol, 81, 160-5.
  5. Brooks SE, Zhan M, Cote T, Baquet CR(2004). Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol, 93, 204.
  6. Casali PG, Blay JY (2010). Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 198-203.
  7. Chan JK, Kawar NM, Shin JY, et al (2008). Endometrial stromal sarcoma: a population- based analysis. Br J Cancer, 99, 1210-5.
  8. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR (1990). Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol, 14, 415-38.
  9. Chu MC, Mor G, Lim C, et al (2003). Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol, 90, 170-6.
  10. Durnali A, Tokluoglu S, Ozdemir N, et al (2012). Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey. Asian Pac J Cancer Prev, 13, 1935-41
  11. Echt G, Jepson J, Steel J, et al (1990). Treatment of uterine sarcomas. Cancer, 66, 35-9.<35::AID-CNCR2820660108>3.0.CO;2-V
  12. Gadducci A, Sartori E, Landoni F,et al (1996). Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol, 63, 247-53.
  13. Gadducci A, Cosio S, Romanini A, Genazzani AR (2008). The management of patients with uterine sarcoma: A debated clinical challenge. Crit Rev Oncol Hematol, 65, 129-42.
  14. Gadduci A (2011). Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol, 25, 783-95.
  15. Garg G, Shah JP, Toy EP, et al (2010). Stage IA vs IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol, 118, 8-13.
  16. Geller MA, Argenta P, Bradley W, et al (2004). Treatment and recurrence in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol, 95, 632-6.
  17. Ghaemmaghami F, Zarchi MK, Gilani MM, et al (2008). Uterine sarcoma: Clinicopathological characteristics, treatment and outcome in İran. Asian Pac J Cancer Prev, 9, 421-6.
  18. Goff BA, Rice LW, Fleishhacker D, et al (1993). Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol, 50, 105-9.
  19. Haberal A, Kayikcioglu F, Boran N, et al (2003). Endometrial stromal sarcoma of the uterus: analysis of 25 patients. Eur J Obstet Gynecol Reprod Biol, 109, 209-13.
  20. Ihnen M, Mahner S, Jänicke F, Schwarz J (2007). Current treatment options in uterine endometrial stromal sarcoma: Report of a case and review of the literature. Int J Gynecol Cancer, 17, 957-63.
  21. Koss LG, Spiro RH, Brunschwig A (1965). Endometrial stromal sarcoma. Surg Gynecol Obstet, 121, 531-7.
  22. Larson B, Silfversward C, Nilsson B, Pettersson F (1990). Endometrial stromal sarcoma of the uterus. A clinical and histopathological study. The Radiumhemmet series 1936-1981. Eur J Obstet Gynecol Reprod Biol, 35, 239-49.
  23. Leath CA, Huh WK, Hyde J, et al (2007). A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol, 105, 630-4.
  24. Li AJ, Giuntoli RL, Drake R, et al (2005). Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol, 106, 1304-8.
  25. Li N, Wu LY, Zhang HT, et al (2008). Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases. Gynecol Oncol, 108, 306-11.
  26. Malouf GG, Duclos J, Rey A, et al (2010). Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. Ann Oncol, 21, 2102-6.
  27. Maluf FC, Sabatini P, Schwartz L, Xia J, Aghajanian C (2001). Endomerial stromal sarcoma: objective response to letrozole. Gynecol Oncol, 82, 384-8.
  28. Mansi J.L, Ramachandra S, Wiltshaw E, Fisher C (1990). Endometrial stromal sarcomas. Gynecol Oncol, 36, 113-8.
  29. Moinfar F, Azodi M, Tavassoli FA (2007). Uterine sarcomas. Pathology, 39, 55-71.
  30. Nicolas ML, Cathro HP, Kerr SE, Stelow EB (2007). Cytomorphologic features of low-grade endometrial stromal sarcoma. AJR Am J Clin Pathol, 128, 265-71.
  31. Nicolas ML, Cathro HP, Kerr SE, Stelow EB (2007). Cytomorphologic features of low-grade endometrial stromal sarcoma. AJR Am J Clin Pathol, 128, 265-71.
  32. Norris HJ, Taylor HB (1966). Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer, 19, 755-66.<755::AID-CNCR2820190604>3.0.CO;2-U
  33. Prat J (2009). FIGO staging for uterine sarcomas. Int J Gynaecol Obstet, 104, 177-8.
  34. Rauh-Hain JA, del Carmen MG (2013). Endometrial stromal sarcoma: a systematic review. Obstet Gynecol, 122, 676-83.
  35. Reich O, Winter R, Regauer S (2005). Should lymphadenectomy be performed in patients with endometrial stromal sarcoma? Gynecol Oncol, 97, 982-3.
  36. Riopel J, Plante M, Renaud MC, Roy M, Tetu B (2005). Lymph node metastases in low- grade endometrial stromal sarcoma. Gynecol Oncol, 96, 402-6.
  37. Sagage S, Yamashita K, Ishioka S, et al (2004). Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology, 67, 33-9
  38. Spano JP, Soria JC, Kambouchner M, et al (2003). Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol, 20, 87-93.
  39. Tanz R, Mahfoud T, Bazine A, et al (2012). Endometrial stromal sarcoma: prognostic factors and impact of adjuvant therapy in early stages. Hematol Oncol Stem Cell Ther, 5, 31-5.
  40. Tavassoli FA, Devilee P(2003) .World Health Organization classification of tumors. Mesenchymal tumors and related lesions. In: 'Pathology and genetics of tumors of the breast and female organs', Eds.Tavassoli FA and Devilee P. IARC Press, Lyon( France), 233-6.
  41. Weitmann HD, Knocke TM, Kucera H, Potter R (2001). Radiation therapy in the treatment of stromal sarcoma. Int J Radiat Oncol Biol Phys, 41, 739-48.
  42. Xue WC, Cheung AN (2011). Endometrial stromal sarcoma of the uterus. Best Pract Res Clin Obstet Gynaecol, 25, 719-32.
  43. Yamawaki T, Shimizu Y, Hasumi K (1997). Treatment of stage IV "high-grade" endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin. Gynecol Oncol, 64, 265-9.